Gregg Coodley, MD
Internal Medicine · Portland, ORNPI 1871593491
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $803, 5.0 times the $159 reported in 2019. Among internal medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$598
- Amgen$444
- AbbVie$298
- Lilly USA, LLC$229
- Gilead$197
- GSK$186
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,182100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 36 | $598 |
| Amgen(2 entities) | 23 | $444 |
| AbbVie(2 entities) | 14 | $298 |
| Lilly USA, LLC | 9 | $229 |
| Gilead | 10 | $197 |
| GSK | 8 | $186 |
| Merck | 11 | $186 |
| Boehringer Ingelheim | 7 | $180 |
| Novartis | 8 | $165 |
| Abbott | 5 | $101 |
| AstraZeneca | 4 | $66 |
| Vanda Pharmaceuticals Inc. | 2 | $62 |
| Bayer | 4 | $60 |
| Exact Sciences | 3 | $56 |
| Pfizer | 3 | $52 |
| Boston Scientific | 2 | $51 |
| Novo Nordisk | 2 | $31 |
| Lundbeck LLC | 1 | $28 |
| Dexcom, Inc. | 1 | $28 |
| Medtronic | 1 | $26 |
| Braemar Manufacturing, LLC | 1 | $24 |
| Johnson & Johnson | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $13 |
How this compares
$3,182 in reported general payments places this provider in the 95th percentile of 1,363 internal medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 33 | $122,704 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 25 | $107,198 |
| JardianceEmpagliflozin | 75 | $104,355 |
| EliquisApixaban | 82 | $89,359 |
| XareltoRivaroxaban | 50 | $71,678 |
| DescovyEmtricitabine/Tenofov Alafenam | 25 | $57,656 |
| RybelsusSemaglutide | 40 | $50,925 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $44,830 |
| MounjaroTirzepatide | 39 | $44,364 |
| FarxigaDapagliflozin Propanediol | 37 | $42,100 |
| IsentressRaltegravir Potassium | 15 | $39,007 |
| EntrestoSacubitril/Valsartan | 36 | $37,627 |
| TivicayDolutegravir Sodium | 12 | $25,660 |
| Darunavir | 32 | $20,369 |
| Spiriva RespimatTiotropium Bromide | 20 | $12,952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya, Descovy | $197 | $164,85450 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $180 | $117,30795 claims |
| PfizerEliquis | $52 | $89,35982 claims |
| Johnson & JohnsonXarelto | $22 | $71,67850 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $598 | $70,49025 claims |
| Novo NordiskRybelsus | $31 | $50,92540 claims |
| Lilly USA, LLCMounjaro | $229 | $44,36439 claims |
| AstraZenecaFarxiga | $66 | $42,10037 claims |
| MerckIsentress | $186 | $39,00715 claims |
| NovartisEntresto | $165 | $37,62736 claims |
| GSKTrelegy Ellipta | $186 | $10,74012 claims |
| AbbVieSynthroid | $298 | $1,87134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 internal medicine providers in Oregon.
Other internal medicine in Portland
- Pranav ChandrashekarPortland$81K
- Jessica CastlePortland$66K
- Stephen SpurgeonPortland$42K
- Jane BabiarzPortland$30K
- Andrew HarbisonPortland$29K
- Bertram BerneyPortland$19K
- George DemetrionPortland$13K
- Joshua GenstlerPortland$9K
- Y Pritham RajPortland$9K
- James BergtholdPortland$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.